List of Medical Device Companies in United Kingdom - 29

The market for polymeric biomaterials is growing quickly, but despite this growth, it is widely recognised in the industry that the ‘holy grail’ solution has not yet been developed. The ideal biomaterial for use in regenerative medicine must: be biocompatible; promote tissue regeneration; have non-toxic biodegradation, have mechanical properties suited to the host tissue and good handling properties in a clinical environment. Our people have developed a patented range of novel polymeric 3-D printing resin-inks that promise, uniquely, to meet all of the above requirements and offer important advantages over the next best alternatives. The polymers and their degradation products are non-toxic and their properties can be tuned to suit a wide range of tissue regeneration applications. These 3-D printable resin-inks will enable medical implants to be fitted to the exact shape and dimensional requirements of each patient, optimising outcomes in applications such as cancer treatment, degenerative spinal conditions and reconstructive surgery. Initial in-vitro and in-vivo testing has provided strong evidence of the anticipated biocompatibility and tissue regeneration properties that will enable multiple stakeholders in the health sector to benefit from improved treatment options for a range of life-changing conditions, not least the patients themselves.

We are lateral flow CDMO experts based in the UK supporting global customers bring their assays to market, from proof of concept, through optimisation and scale up to routine manufacture, along with full-service regulatory consultancy support. Get in touch: email info@abingdonhealth.com today. We believe that by developing the high quality, effective lateral flow rapid tests combined with our manufacturing experience and scale, we can provide the means to accelerate access to rapid testing. This means faster diagnosis and screening in the field, accelerating the ability of decision makers to deploy a more rapid response to results. We are committed and honest in all that we do. We value the quality and contribution of all, priding ourselves on building long-lasting and trusting partnerships – because by working transparently with customers, partners and colleagues, we are better together. With an exceptional pedigree in developing and manufacturing rapid tests Abingdon Health are expert in responding to our customers varied needs with specific and customisable solutions. Our mission: To improve life by making rapid results accessible to all. By providing the best lateral flow rapid test solutions, we believe we can support the increase in access to diagnostics across many industries and locations throughout the world. Faster access to results allows for rapid decision making and solutions. This ability has a significant role to play in improving life in so many ways.

Alesi Surgical announced in 2023 that it had attained FDA clearance for its groundbreaking Ultravision2 smoke management solution. The breakthrough new Ultravision system includes the world's first surgical tool integrating electrosurgery and class-leading surgical smoke control in a single laparoscopic device. Alesi Surgical was founded to develop and commercialise products that improve the safety, efficacy, and outcomes of surgical procedures. The company is a spin-out of the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experienced surgeons, surgical trainers, and trainees, which allows it to identify issues in procedures and design devices to address these issues. The company is active in the research and development of novel surgical technologies. It has a ‘needs-driven' pipeline and product development is informed by robust testing by surgical trainers who advise on the utility, usability, and integration of products into surgical practice. Ultravision is designed to deliver rapid and continuous resolution of surgical smoke. It is a small, stand-alone, portable unit fully compatible with current laparoscopic equipment and electrosurgical instruments. Alesi Surgical welcomes approaches from research-based companies or inventors who are interested in exploring potential synergies.

Amber Therapeutics was founded in 2021 with a mission to develop and deliver breakthrough neuromodulation therapies that can fundamentally restore normal physiological function in women suffering with mixed urinary incontinence. The company's first therapy, Amber UI, is an intelligent closed-loop bioelectrical therapy for urge and mixed urinary incontinence. The startup has also acquired Bioinduction, a fellow U.K.-based company and the maker of the Picostim DyNeuMo platform.

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 100,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

Caristo Diagnostics has been formed to bring revolutionary cardiovascular diagnostic tools to patients worldwide. Our proprietary technology transforms the accuracy of routine cardiac CT scans by extracting new information that is otherwise invisible, greatly enhancing the power to predict cardiovascular risk and refine treatment decisions. Our Website: https://www.caristo.com Follow us on Twitter: https://twitter.com/CaristoHeart

At Convatec, #ForeverCaring is our promise to patients & healthcare providers, as we deliver pioneering trusted medical solutions to improve the lives we touch. #ForeverConvatec

As a leader in orthopaedic innovation, Corin has pioneered a number of landmark developments since its foundation and is proud to have been able to improve the quality of life of thousands of patients around the world through these groundbreaking products. The company's talented and dedicated teams share a common commitment to deliver quality orthopaedic products and services to patients, surgeons and healthcare providers which exceed expectations and positively impact lives. With an increasingly active and demanding patient population, the need to provide state of the art conservative treatment pathways, in addition to more traditional interventions, has never been more important. Corin's product portfolio is designed to provide each patient with the optimal solution, utilising some of the most advanced technologies available in the world to enhance implant longevity and performance.

At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. Our integrated electrosurgery unit delivers Bipolar Radiofrequency for precise dissection and resection and Microwave energy for controlled ablation and coagulation. This technology sets a new standard for Endoscopic Submucosal Dissection with our new Speedboat RS2 instrument: the Bipolar Radiofrequency cut allows precise dissection and the microwave coagulation provides controlled haemostasis while the protective hull reduces the risk of muscle damage and the integrated injection needle helps to maintain submucosal lift without instrument changes.

Cumulus Neuroscience is a global digital health company focused on advancing neuroscience clinical trials and research. They collaborate with leading global pharmaceutical companies to meet the industry's complex clinical trial needs. Cumulus Neuroscience offers a unique career and is known for its innovative assessment platform for identifying brain disorders.

Dyneval’s innovative technology provides precise measurement of semen quality using portable equipment. It is the first technology capable of measuring the lifetime of semen motility in quasi- in-vivo conditions, thus providing new insights into the behaviour of spermatozoa prior to conception. We are fulfilling our vision to become the experts’ choice for semen quality assessment. Vets and genetics companies are using this data to inform breeding plans and confirm quality at every stage across the supply chain to ensure that livestock production is more efficient, improving food security while reducing the intensity of methane emissions.

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland. Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with Acute Kidney Injury receiving CRRT and patient on Renal replacement Therapy receiving Peritoneal Dialysis. Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Complement activation has also been associated with Peritoneal Dialysis(PD) and may be a driver of fibrotic changes that limit PD duration.

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. Our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. At LivaNova, we understand the importance of bringing both clinical and economic value to our customers. We are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. LivaNova is listed on the NASDAQ stock exchange under the ticker symbol "LIVN." LivaNova has approximately 2,900 employees worldwide. We are headquartered in London (UK) and maintain a presence in more than 100 countries. LivaNova is a worldwide leader in cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.

Locate Bio bring together Programmed Drug Release and Instructive Tissue Scaffolds to develop the next generation of products with significant disruptive potential for musculoskeletal conditions.

Magstim is a neurotechnology company that specializes in advanced brain stimulation and monitoring technologies. Founded in 1988 and headquartered in Whitland, Carmarthenshire, UK, Magstim is dedicated to advancing neurophysiology and neuromodulation. The company serves neuroscience researchers and clinicians globally, aiming to improve patient care for neurological and psychiatric disorders. Magstim develops and manufactures a range of precision neurotechnology tools. Their offerings include Transcranial Magnetic Stimulation (TMS) devices for non-invasive brain stimulation, high-density Electroencephalography (EEG) systems for monitoring brain activity, and transcranial Direct Current Stimulation (tDCS) devices for modulating neuronal activity. They also provide neurodiagnostic solutions, such as surgical nerve monitoring and intraoperative neurophysiology technologies. With a customer base that spans the globe, Magstim's products are utilized in research and treatment for conditions like depression, Parkinson’s disease, and epilepsy. Their tools have been referenced in over 20,000 clinical papers, highlighting their significant contribution to the field of brain science.

MediSieve is a London biotech start-up developing Magnetic Haemofiltration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. A unique, lifesaving and often cost-saving solution, there are several multi-billion-dollar markets available for this product in oncology, infectious diseases, auto-immune diseases, poisoning, drug overdose and others. Magnetic Haemofiltration has already been shown to rapidly, specifically, and effectively remove IL-6 from human plasma. The technology has completed pre-clinical validation, including animal studies, and is expected to start clinical studies in Q2 2022. MediSieve has raised £4M in equity funding and over £4M in non-dilutive grants. Seeking a further £8M at Series A to support pivotal clinical trials and regulatory approvals. EIS eligible. The company has been featured in numerous online and print media articles, including the Sunday Telegraph, Daily Mail, and Wired Magazine, and been winner or finalist in several start-up competitions such as Pitch@Palace, MassChallenge, OBN Awards, TCT Magazine Awards and CMS Healthcare Startup of the Year. Recently, our founder George Frodsham was awarded BBSRC Innovator of the Year and MIT Innovators Under 35.

Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan and a joint venture in China. For more information, please visit www.mevion.com. About the MEVION S250 Series: The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The Series is comprised of: • MEVION S250, offering highly stable, next-generation volumetric delivery capabilities • MEVION S250i with HYPERSCAN technology, overcoming pencil beam scanning uncertainties by delivering robust Intensity Modulated Proton Therapy treatment at hyper-speed • MEVION S250mx, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and guarantee 100 percent facility uptime

We are pioneering the use of semiconductor technology for next-generation neural implants. Our mission is to provide the best possible outcomes for patients with neurological conditions by delivering the highest performance with the least invasive surgery. Our team brings together world-class experts in neuroscience, microtechnology, and implantable neural interfaces — augmented with medtech industry pedigree and clinical experience.

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world's leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients' products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry's premier, trusted partner for successful development and commercialization outcomes. Learn more: https://namsa.com/about/client-testimonials/

Neurochase was founded by a team of physician-scientists led by Professor Steven Gill in response to the growing need for CED consultancy services in the life science industry. Professor Gill is an Honorary Professor of Neurosurgery at the University of Bristol. He is a world leading expert in CED and has spent the past 20 years developing technology to facilitate highly accurate and safe targeting of deep brain structures using software and surgical robots. To learn more about Professor Gill, watch the following video interview where he discusses his clinical experience of intermittently delivering chemotherapy directly to paediatric brainstem tumours using his novel implantable neurosurgical device. Our Science: Convection Enhanced Delivery (CED) provides a method of achieving effective doses of therapeutics homogenously in targeted brain volumes that cannot be achieved safely with systemic or CSF delivery. Therapies are infused into the brain via micro-catheters and can be distributed in tightly controlled doses throughout the required treatment volume. The blood brain barrier now acts to retain the therapy in the brain targets thereby minimising systemic and off-target exposure. We believe that safe and scalable delivery of novel therapeutics by CED is achievable and will transform human health by unlocking treatments to previously untreatable neurological disorders.

Based in Belfast, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges! Modius is the first product from Neurovalens which successfully launched in August 2017 on Indiegogo. Modius was designed to help improve the lives of people who struggle with their weight by using neuro-technology to help make weight loss easier.

Welcome to the Phagenesis LinkedIn page!  At Phagenesis, we are dedicated to transforming the way dysphagia is treated. Dysphagia, or difficulty swallowing, can be a debilitating condition that affects millions of people worldwide. We believe that everyone deserves the ability to enjoy their meals and live their lives to the fullest, which is why we have developed the Phagenyx - a revolutionary product that uses Pharyngeal Electrical Stimulation (PES) to treat dysphagia.  The Phagenyx is a simple, non-invasive device that stimulates the nerves in the pharynx, helping patients regain control of their swallowing function. Our product has been rigorously tested in clinical trials and has been shown to significantly improve swallowing ability in patients with dysphagia.  As a company, we are committed to advancing the field of dysphagia care through innovative technology and evidence-based practices. We work closely with healthcare providers and patients to ensure that our product meets the highest standards of safety and efficacy.  We are proud to be changing the paradigm of dysphagia care, and we invite you to join us in our mission to improve the lives of millions of people around the world. Follow our page to stay up-to-date on the latest news and developments in dysphagia care, and to learn more about the Phagenyx and how it is helping patients overcome dysphagia.

PulmoBioMed commercialises state-of-the-art exhaled breath condensate & aerosol sampling technology as part of a platform for disease and environmental diagnostics. Our lead product, PBM-HALE is a passive fluid aerosol sampler engineered to segregate exhaled and environmental particles by size. Our technology solves key pains in avoiding sample contamination, preventing sample loss and generating highly reproducible data with digital molecular precision. The first of a series of products, PBM-HALE has demonstrated utility in biological agent capture, genomic/microbiomic analytics, and metabolomic profiling, through a one-stop solution. Our vision is to develop the first hand-held biomolecular analyser for medical, veterinary, well-being and environmental use. Our mission is to deliver molecular diagnostic-grade health data from your lips to your hand. PulmoBioMed Ltd. is a Northumbria University spinout company supported by the Northern Accelerator, iCURe, and InnovateUK.

Quanta Dialysis Technologies is committed to making high-quality and cost-effective dialysis accessible to every patient in every setting with its Quanta Dialysis System - the first and only FDA-cleared device to perform IHD, SLED, and CRRT (CVVHD and SCUF) without any need for bags. As a compact device with performance comparable to larger traditional machines, the Quanta Dialysis System provides the clinical versatility needed to deliver kidney replacement therapy across multiple care settings. With an intuitive user interface and only once-weekly hot rinse requirement, the device is designed to be operated by a broad range of users to bring dialysis directly to patients. The Royal Academy of Engineering announced Quanta Dialysis Technologies as the recipient of the 2022 MacRobert Award (the UK’s longest running and most prestigious award for UK engineering innovation), joining the ranks of Rolls-Royce, Arup and Raspberry Pi.

Rayner manufactured the world's first IOL in 1949, and has remained at the forefront of innovation for over 70 years, focused on providing you and your patients with the best IOLs and ophthalmic solutions - always driven by science to improve patient outcomes and safety. Rayner is the only manufacturer of IOLs in the UK, with its state-of-the-art manufacturing plant and Global Headquarters on the South Coast of England. Rayner is a fast-paced and growing business with 500+ employees worldwide.

SkinBioTherapeutics is a life science company focused on skin health. SkinBioTherapeutics is targeting five specific healthcare sectors: Cosmetic, Food Supplements, Medical Devices, Hospital and Domestic Surface Hygiene and Pharmaceuticals.

Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. Vectura has thirteen key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork. For further information, please visit Vectura's website at www.vectura.com

Wisdom Sales + Marketing helps small and midsized food companies grow their business. We do this by providing food brokerage services representing food companies in National Retail and Food Service Restaurant Chains Accounts in North America. Many of our customers need more than just sales support to grow as a result we also provide management consulting in the areas of strategic planning, acquisition / divestiture support, ROI marketing analysis, sales and marketing structure and alignment, branding, innovation / product development, advertising, and consumer promotion. If you need help selling or buying a business, or raising capital we may also be able to help.